3 High-Yield Dividends That Pay You Soon (But You Must Act Quickly)

Income investors watching the calendar have a narrow window this week. Three of the market’s most widely held high-yield names are about to lock their next payment rosters, and the buy-by deadlines are close enough that a delayed brokerage order could push readers a full quarter down the line before the next check clears. The trio in focus, Verizon (NYSE:VZ | VZ Price Prediction), AT&T (NYSE:T), and Pfizer (NYSE:PFE), pair yields above the broad market average with coverage profiles that separate them from typical yield traps.

Here is the at-a-glance calendar, followed by a coverage read for each name using the metric that actually matters for its business model.

The Buy-By Calendar

To qualify for any of these payments, shares must be owned by the day BEFORE the ex-dividend date, which for Verizon and AT&T means settling a trade by the close on Thursday, July 9th, 2026. (That’s tomorrow.) Pfizer offers a longer runway, with a buy-by date roughly two weeks out (July 23rd).

Verizon: Free Cash Flow Doing The Heavy Lifting

Verizon trades at $42.82 with a market cap of $177.83 billion, and the stock has slipped 6.13% over the past month, pushing the yield toward the top of its historical range. The quarterly payment of $0.7075 was raised from $0.69 earlier this year, extending a streak that Wells Fargo recently flagged as 21 consecutive years of dividend increases.

For a capital-heavy telecom, free cash flow is the right coverage lens. Management is guiding to free cash flow of $21.5 billion or more in 2026 alongside $3.0 billion-plus in share repurchases, comfortably above dividend commitments. Q1 2026 adjusted EPS came in at $1.28, up 7.6% year over year, on revenue of $34.44 billion. Leverage is the offset: net debt-to-EBITDA sits at 2.6x following the Frontier acquisition that closed January 20, 2026. At a forward multiple of 8, the market is already pricing in that debt load.

AT&T: A Fixed Payout Backed By Rising Cash

AT&T shares last changed hands at $21.27, down 22.53% over the past year. The dividend has held at $0.2775 per quarter for eight consecutive quarters, and management has publicly committed to maintaining that payout through 2028.

Coverage here also runs through free cash flow. Guidance calls for $18 billion-plus in FCF against the dividend plus $8 billion in planned 2026 buybacks, part of a $45 billion-plus shareholder-return program through 2028. Q1 2026 adjusted EPS of $0.57 rose 11.8% year over year, and the company added 584,000 internet subscribers alongside 294,000 postpaid phone net adds. Net debt-to-EBITDA of 2.71x is elevated but trending in the right direction. Wall Street’s average price target sits at $30.24, well above the current quote.

Pfizer: Earnings Coverage With A Patent-Cliff Overhang

Pfizer offers the fattest headline yield of the three at 7.07%, with shares at $24.22 after a 7.57% monthly pullback. For a large-cap pharma, coverage is best measured against adjusted EPS rather than free cash flow, given the lumpiness of R&D and legal outflows. Full-year 2026 guidance of $2.80 to $3.00 in adjusted EPS against an annual dividend of $1.72 leaves the payout ratio in a workable range, even after the company paid $2.4 billion in dividends in Q1 alone.

Growth is coming from the newer portfolio. Padcev rose 39%, Nurtec ODT/Vydura climbed 41%, and the recently launched or acquired basket grew 22% operationally. The pushback is COVID-related revenue rolling off (Comirnaty down 59%, Paxlovid down 63%) plus a $1.5 billion loss-of-exclusivity headwind this year.

What To Watch Next

All three names carry institutional ownership above 69%, which typically muffles the mechanical price drop that follows an ex-dividend date. Verizon and AT&T both offer forward multiples in the single digits (8x and 9x respectively), a rare combination alongside yields north of 5%. Pfizer, at a forward multiple of 8, prices in the patent-cliff drag, so the coverage read matters more than the headline yield. The clock is the shorter-term variable: miss the buy-by deadline, and the next opportunity is roughly three months out.

Contact [email protected] for any questions or corrections.